Zobrazeno 1 - 10 of 67 pro vyhledávání: '"Samuel H. Zwillich"'
1
Akademický článek
The Epidemiology of Hospital-Treated Alopecia Areata in Denmark, 1995–2016
Autor: Sissel Brandt Toft Sørensen, Prethibha George, Oladayo Jagun, Robert Wolk, Lynne Napatalung, Samuel H. Zwillich, Lars Iversen, Vera Ehrenstein
Publikováno v: Dermatology and Therapy, Vol 14, Iss 4, Pp 993-1006 (2024)
Abstract Introduction Alopecia areata (AA) is an autoimmune skin disease presenting as nonscarring hair loss. Information on the epidemiology of AA, especially the occurrence of AA and its subtypes within the general population, is scarce. The study
Externí odkaz: https://doaj.org/article/c57380e937764ae587523e55fe6732cd
Zobrazit plný text záznamu
2
Akademický článek
A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
Autor: Samira Anderson, Guido Cavaletti, Linda J. Hood, Michael Polydefkis, David N. Herrmann, Gary Rance, Brett King, Amy J. McMichael, Maryanne M. Senna, Brian S. Kim, Lynne Napatalung, Robert Wolk, Samuel H. Zwillich, Gregor Schaefer, Yankun Gong, Melanie Sisson, Holly B. Posner
Publikováno v: Pharmacology Research & Perspectives, Vol 12, Iss 4, Pp n/a-n/a (2024)
Abstract Reversible axonal swelling and brainstem auditory evoked potential (BAEP) changes were observed in standard chronic (9‐month) toxicology studies in dogs treated with ritlecitinib, an oral Janus kinase 3/tyrosine kinase expressed in hepatoc
Externí odkaz: https://doaj.org/article/3530c0e1c1d5497d97bb7fe1b83e42ad
Zobrazit plný text záznamu
3
Akademický článek
Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database
Autor: Prethibha George, Oladayo Jagun, Qing Liu, Charles Wentworth, Lynne Napatalung, Robert Wolk, Susan Anway, Samuel H. Zwillich
Publikováno v: Dermatology and Therapy, Vol 13, Iss 8, Pp 1733-1746 (2023)
Abstract Introduction Alopecia areata (AA) is an autoimmune disease with an underlying immuno-inflammatory pathogenesis. Treatments can include systemic corticosteroids and immunomodulators (such as Janus kinase inhibitors); these medications may be
Externí odkaz: https://doaj.org/article/900481aae67742ffb6245160448662a7
Zobrazit plný text záznamu
4
Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review
Autor: Arash Mostaghimi, Boris Gorsh, Randall Winnette, Lynne Napatalung, Samuel H. Zwillich, Jason Xenakis, Vanja Sikirica
Publikováno v: Dermatology and Therapy
Introduction Alopecia areata (AA) is a chronic, autoimmune disease of hair loss, which can significantly affect the emotional and psychological well-being of patients. A systematic literature review was conducted to better understand the burden of AA
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a77165bb1fe0cb4abd0ee3eacf0b230
https://doi.org/10.1007/s13555-021-00512-0
Zobrazit plný text záznamu
7
Phase 1 Dose‐Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers
Autor: So Miyoshi, Samuel H. Zwillich, Shigeyuki Toyoizumi, Sriram Krishnaswami, Hiroyuki Nakamura
Publikováno v: Clinical Pharmacology in Drug Development
The aim of the study was to characterize the pharmacokinetics, safety, and tolerability of tofacitinib, an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in healthy Japanese voluntee
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f58b61815e97914a213125c1ea8a859a
http://europepmc.org/articles/PMC7003739
Zobrazit plný text záznamu
9
Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6
Autor: Samuel H. Zwillich, Bethanie Wilkinson, Eun Bong Lee, Douglass Chapman, Ryan DeMasi, Edward C. Keystone, Lara Fallon, Ronald F van Vollenhoven
Publikováno v: Arthritis Care & Research
Objective Optimal targeted treatment in rheumatoid arthritis requires early identification of failure to respond. This post hoc analysis explored the relationship between early disease activity changes and the achievement of low disease activity (LDA
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1781bb9ad0e2809fdce5872e9f674e3f
http://europepmc.org/articles/PMC6590136
Zobrazit plný text záznamu
10
Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial
Autor: Sriram Krishnaswami, David Gruben, Gene V. Wallenstein, Joel M. Kremer, Samuel H. Zwillich, Vibeke Strand
Publikováno v: Arthritis Care & Research
Objective: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared patient-reported outcomes (PROs) in patients with RA treated with tofacitinib or placebo in combination with conventional disease-mod
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13dce95858e8b7bec7a40581b768dfa3
https://doi.org/10.1002/acr.23004
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje